Which has higher valuation and earnings, KZIA or ATRA?

Atara Biotherapeutics has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 743.60 -$13.41M N/A N/A Atara Biotherapeutics $120.77M 0.60 $32.69M -$0.67 N/A

Does the media favor KZIA or ATRA?

In the previous week, Atara Biotherapeutics had 4 more articles in the media than Novogen. MarketBeat recorded 7 mentions for Atara Biotherapeutics and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat Atara Biotherapeutics' score of -0.33 indicating that Novogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, KZIA or SERA?

Novogen has higher earnings, but lower revenue than Sera Prognostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 743.60 -$13.41M N/A N/A Sera Prognostics $80K 959.42 -$31.93M -$0.65 N/A

Does the media prefer KZIA or SERA?

In the previous week, Sera Prognostics had 5 more articles in the media than Novogen. MarketBeat recorded 8 mentions for Sera Prognostics and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat Sera Prognostics' score of -0.16 indicating that Novogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, KZIA or GANX?

Novogen has higher earnings, but lower revenue than Gain Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 743.60 -$13.41M N/A N/A Gain Therapeutics $50K 1,850.34 -$20.16M -$0.58 N/A

Is KZIA or GANX more profitable?

Novogen's return on equity of 0.00% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Gain Therapeutics N/A -161.59% -118.36%

Does the media prefer KZIA or GANX?

In the previous week, Gain Therapeutics had 6 more articles in the media than Novogen. MarketBeat recorded 9 mentions for Gain Therapeutics and 3 mentions for Novogen. Gain Therapeutics' average media sentiment score of 1.01 beat Novogen's score of 0.96 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CYPH or KZIA?

Cypherpunk Technologies has higher earnings, but lower revenue than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M $0.56 1.15 Novogen $30K 743.60 -$13.41M N/A N/A

Is CYPH or KZIA more profitable?

Novogen's return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -20.76% -19.48% Novogen N/A N/A N/A

Does the media refer more to CYPH or KZIA?

In the previous week, Cypherpunk Technologies had 3 more articles in the media than Novogen. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat Cypherpunk Technologies' score of 0.55 indicating that Novogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, KZIA or IBIO?

Novogen has higher earnings, but lower revenue than iBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 743.60 -$13.41M N/A N/A iBio $400K 177.61 -$18.38M -$0.58 N/A

Is KZIA or IBIO more profitable?

Novogen's return on equity of 0.00% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A iBio N/A -53.86% -46.48%

Does the media favor KZIA or IBIO?

In the previous week, Novogen had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Novogen and 2 mentions for iBio. iBio's average media sentiment score of 1.45 beat Novogen's score of 0.96 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Novogen (KZIA) Competitors

$13.52 +0.31 (+2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$13.55 +0.03 (+0.22%)

As of 07:34 PM Eastern

Compare

KZIA vs. ATRA, SERA, GANX, CYPH, and IBIO

Should you buy Novogen stock or one of its competitors? Novogen's main competitors and comparable companies include Atara Biotherapeutics (ATRA), Sera Prognostics (SERA), Gain Therapeutics (GANX), Cypherpunk Technologies (CYPH), and iBio (IBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Novogen compare to Atara Biotherapeutics?

Novogen (NASDAQ:KZIA) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Novogen has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

Novogen has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Novogen's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

Atara Biotherapeutics has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	743.60	-$13.41M	N/A	N/A
Atara Biotherapeutics	$120.77M	0.60	$32.69M	-$0.67	N/A

In the previous week, Atara Biotherapeutics had 4 more articles in the media than Novogen. MarketBeat recorded 7 mentions for Atara Biotherapeutics and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat Atara Biotherapeutics' score of -0.33 indicating that Novogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.9% of Novogen shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novogen currently has a consensus target price of $26.33, indicating a potential upside of 94.77%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential upside of 17.43%. Given Novogen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Novogen is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Novogen beats Atara Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Novogen compare to Sera Prognostics?

Novogen (NASDAQ:KZIA) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Novogen has higher earnings, but lower revenue than Sera Prognostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	743.60	-$13.41M	N/A	N/A
Sera Prognostics	$80K	959.42	-$31.93M	-$0.65	N/A

Novogen has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Novogen's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

30.9% of Novogen shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Sera Prognostics had 5 more articles in the media than Novogen. MarketBeat recorded 8 mentions for Sera Prognostics and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat Sera Prognostics' score of -0.16 indicating that Novogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Novogen has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Novogen currently has a consensus price target of $26.33, indicating a potential upside of 94.77%. Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 180.61%. Given Sera Prognostics' higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Novogen beats Sera Prognostics on 8 of the 15 factors compared between the two stocks.

How does Novogen compare to Gain Therapeutics?

Novogen (NASDAQ:KZIA) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

30.9% of Novogen shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novogen has higher earnings, but lower revenue than Gain Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	743.60	-$13.41M	N/A	N/A
Gain Therapeutics	$50K	1,850.34	-$20.16M	-$0.58	N/A

Novogen's return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Gain Therapeutics	N/A	-161.59%	-118.36%

Novogen has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Novogen currently has a consensus price target of $26.33, suggesting a potential upside of 94.77%. Gain Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 253.77%. Given Gain Therapeutics' higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Gain Therapeutics had 6 more articles in the media than Novogen. MarketBeat recorded 9 mentions for Gain Therapeutics and 3 mentions for Novogen. Gain Therapeutics' average media sentiment score of 1.01 beat Novogen's score of 0.96 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gain Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novogen beats Gain Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Novogen compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Novogen's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-20.76%	-19.48%
Novogen	N/A	N/A	N/A

Cypherpunk Technologies has higher earnings, but lower revenue than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	1.15
Novogen	$30K	743.60	-$13.41M	N/A	N/A

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cypherpunk Technologies had 3 more articles in the media than Novogen. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat Cypherpunk Technologies' score of 0.55 indicating that Novogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cypherpunk Technologies has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Novogen has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

Cypherpunk Technologies presently has a consensus target price of $0.90, suggesting a potential upside of 39.75%. Novogen has a consensus target price of $26.33, suggesting a potential upside of 94.77%. Given Novogen's stronger consensus rating and higher probable upside, analysts clearly believe Novogen is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Novogen beats Cypherpunk Technologies on 9 of the 13 factors compared between the two stocks.

How does Novogen compare to iBio?

Novogen (NASDAQ:KZIA) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Novogen has higher earnings, but lower revenue than iBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	743.60	-$13.41M	N/A	N/A
iBio	$400K	177.61	-$18.38M	-$0.58	N/A

In the previous week, Novogen had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Novogen and 2 mentions for iBio. iBio's average media sentiment score of 1.45 beat Novogen's score of 0.96 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iBio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novogen has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, iBio has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Novogen's return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
iBio	N/A	-53.86%	-46.48%

Novogen presently has a consensus price target of $26.33, indicating a potential upside of 94.77%. iBio has a consensus price target of $5.00, indicating a potential upside of 249.65%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

Novogen beats iBio on 8 of the 14 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.84M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	N/A	10.67	269.06	25.28
Price / Sales	743.60	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-2.53	16.78	12.91	6.24
Net Income	-$13.41M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-2.66%	1.74%	1.12%	1.07%
1 Month Performance	0.37%	1.60%	1.79%	1.03%
1 Year Performance	63.48%	56.43%	67.69%	20.77%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	3.5359 of 5 stars	$13.52 +2.3%	$26.33 +94.8%	+56.2%	$21.84M	$30K	N/A	12	Analyst Forecast
ATRA Atara Biotherapeutics	1.9326 of 5 stars	$8.54 -2.6%	$9.50 +11.2%	-29.8%	$76.95M	$120.77M	N/A	330	Earnings Report Gap Down
SERA Sera Prognostics	2.6754 of 5 stars	$1.94 +0.4%	$5.50 +183.8%	-12.6%	$75.89M	$80K	N/A	120	News Coverage Earnings Report Gap Up High Trading Volume
GANX Gain Therapeutics	2.8247 of 5 stars	$1.76 +0.1%	$7.50 +325.9%	+39.4%	$75.11M	$50K	N/A	20	Positive News Earnings Report Analyst Forecast
CYPH Cypherpunk Technologies	3.3169 of 5 stars	$0.68 -1.4%	$0.90 +32.4%	+91.2%	$72.39M	N/A	N/A	40	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. ATRA, SERA, GANX, CYPH, and IBIO

How does Novogen compare to Atara Biotherapeutics?

Summary

How does Novogen compare to Sera Prognostics?

Summary

How does Novogen compare to Gain Therapeutics?

Summary

How does Novogen compare to Cypherpunk Technologies?

Summary

How does Novogen compare to iBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. ATRA, SERA, GANX, CYPH, and IBIO

How does Novogen compare to Atara Biotherapeutics?

Which has more risk & volatility, KZIA or ATRA?

Is KZIA or ATRA more profitable?

Which has higher valuation and earnings, KZIA or ATRA?

Does the media favor KZIA or ATRA?

Do institutionals & insiders believe in KZIA or ATRA?

Do analysts recommend KZIA or ATRA?

Summary

How does Novogen compare to Sera Prognostics?

Which has better earnings & valuation, KZIA or SERA?

Is KZIA or SERA more profitable?

Do institutionals and insiders hold more shares of KZIA or SERA?

Does the media prefer KZIA or SERA?

Which has more volatility & risk, KZIA or SERA?

Do analysts recommend KZIA or SERA?

Summary

How does Novogen compare to Gain Therapeutics?

Do insiders & institutionals hold more shares of KZIA or GANX?

Which has preferable earnings & valuation, KZIA or GANX?

Is KZIA or GANX more profitable?

Which has more risk and volatility, KZIA or GANX?

Do analysts rate KZIA or GANX?

Does the media prefer KZIA or GANX?

Summary

How does Novogen compare to Cypherpunk Technologies?

Is CYPH or KZIA more profitable?

Which has preferable valuation & earnings, CYPH or KZIA?

Do insiders & institutionals have more ownership in CYPH or KZIA?

Does the media refer more to CYPH or KZIA?

Which has more volatility & risk, CYPH or KZIA?

Do analysts recommend CYPH or KZIA?

Summary

How does Novogen compare to iBio?

Do institutionals and insiders have more ownership in KZIA or IBIO?

Which has stronger earnings and valuation, KZIA or IBIO?

Does the media favor KZIA or IBIO?

Which has more volatility and risk, KZIA or IBIO?

Is KZIA or IBIO more profitable?

Do analysts rate KZIA or IBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools